Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an
estimated 17.9 million lives each year, representing one third of global mortality. As existing …

Highlights•Nanomedicine approaches are being explored for managing atherosclerosis.•
Functionalized SPION, USPIO and​ polymeric nanoparticles have been used for active …

Atherosclerosis, being an inflammation-associated disease, represents a considerable
healthcare problem. Its origin remains poorly understood, and at the same time, it is …

Cardiovascular diseases (CVDs) constitute a predominant cause of both global mortality
and morbidity. To address the challenges in the early diagnosis and management of CVDs …

Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality globally.
Despite significant advancements in the development of pharmacological therapies, the …

Cardiovascular diseases (CVDs) present a significant threat to health, with traditional
pharmaceuticals for their treatment being hindered by inefficiencies due to non-targeted …

Cardiovascular disease is the most common health problem worldwide and remains the
leading cause of morbidity and mortality. Despite recent advances in the management of …

Atherosclerosis (AS) is the main pathological cause of coronary heart disease (CHD).
Current clinical interventions including statin drugs can effectively reduce acute myocardial …

Nanoparticles are exclusively suitable for studying and developing potential therapies
against cardiovascular diseases (CVD) because of their size, fine-tunable properties, and …

Atherosclerotic plaques and thrombosis are chronic inflammatory complications and the
main manifestations of cardiovascular diseases (CVD), the leading cause of death globally …